drugset / Trial / NCT07096453
CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients
RandomizedParallel-groupOpen-labelPrevention
Summary
The purpose of this study is to study how CMVIG interacts with the body and to see if it might work to prevent kidney transplant patients from becoming infected with CMV.
Timeline
- Start
- 2025-10-02
- Primary completion
- 2027-08
- Completion
- 2027-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cytogam | Protein / enzyme biologic | 150 mg/kg | — |